CreatorsPublishersAdvertisers
View more in
Cancer

Investigational BTK Inhibitor Shows Promise in Chronic, Small Lymphocytic Leukemia

pharmacytimes.com
 2021-09-09

Cover picture for the articleThe efficacy of pirtobrutinib does not depend on prior therapy, reason for prior BTK inhibitor discontinuation, or C481 mutation status, according to the presentation. Pirtobrutinib, a next-generation, highly selected, non-covalent Bruton tyrosine kinase (BTK) inhibitor, shows significant promise for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL),...

www.pharmacytimes.com

Comments / 0

Comments / 0